Phaseline

Companies › AlgoTherapeutix

AlgoTherapeutix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATX01 10%
Amitriptyline hydrochloride topical formulation; tricyclic antidepressant with analgesic p
SLC6A4, SLC6A3Phase 2Chemotherapy-induced Peripheral Neuropathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05593614ATX01 10%Phase 2Chemotherapy-induced Peripheral NeuropathyNeurologySep 2024

Targets

SLC6A4 (1) SLC6A3 (1)

Companies with the same targets

Otsuka Resilient Pharmaceuticals Remedy Definium Therapeutics US Axsome Therapeutics Intra-Cellular Therapies SK Life Science Takeda CSPC ZhongQi Pharmaceutical Technology Currax Pharmaceuticals

Companies built like this

Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.